TIME SUNDAY/JUNE 2

10.30 ▶ Arrival & Registration

12.00 ▶ Lunch

13.00 ▶ Welcome

13.15 ▶ Virtual Meeting Session I

15.00 ▶ Coffee Break

15.30 ▶ Virtual Meeting Session II

17.30 ▶ End of Scientific Program

TIME TUESDAY/JUNE 408.30 ▶ Highlights previous day

08.35 ▶ Virtual Meeting Session VII

10.00 ▶ Coffee Break

10.30 ▶ Virtual Meeting Session VIII

12.00 ▶ Lunch

13.15 ▶ Virtual Meeting Session IX

14.00 ▶ Live in Chicago

15.00 ▶ Coffee Break

15.30 ▶ Virtual Meeting Session X

17.30 ▶ End of Scientific Program

TIME MONDAY/JUNE 308.30 ▶ Highlights previous day

08.35 ▶ Virtual Meeting Session III

10.00 ▶ Coffee Break

10.30 ▶ Virtual Meeting Session IV

12.00 ▶ Lunch

13.15 ▶ Virtual Meeting Session V

14.00 ▶ Live in Chicago

15.00 ▶ Coffee Break

15.30 ▶ Virtual Meeting Session VI

17.30 ▶ End of Scientific Program

▶ BBQ

TIME WEDNESDAY/JUNE 508.30 ▶ Highlights previous day

08.35 ▶ Virtual Meeting Session XI

10.00 ▶ Coffee Break

10.30 ▶ Virtual Meeting Session XII

11.45 ▶ Practice Changing Highlights ASCO Annual Meeting 2019

12.00 ▶ Lunch

13.15 ▶ Departure

ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored product, event or publication. The mention of any company, product, service, or therapy does not constitute an endorsement of any kind by ASCO.

Organizer Founding Sponsor Co-Sponsors

Sunday / June 2, 2019 Educational or Abstract Title Presenter Duration Link VM

10:00 SC & Organizer Meeting

10:30

Arrival & Registration

Attendees

12:00-13:00 Lunch

13:00-13:15 Welcome SC

13:15-15:00

Chairmen

VM Session I - 1h45

Abstract #

Chair: J. Beyer Edu Uses for PSMA Diagnostics and Therapeutic Approaches in Localized Disease: A Urologist's Perspective Robert Evan Reiter 15min https://meetinglibrary.asco.org/record/167970/video

Chair: J. Beyer 5001 Short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free

survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized Christian Carrie summary by Jörg Beyer, PPT

Chair: J. Beyer 5007 Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing

enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.Bertrand F. Tombal 11min https://meetinglibrary.asco.org/record/172905/video

Chair: J. Beyer 5008 Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone

(ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)Michael J. Morris 11min https://meetinglibrary.asco.org/record/172903/video

Chair: J. Beyer 5005 TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for

metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.Joaquin Mateo 12min https://meetinglibrary.asco.org/record/172904/videoChair: N. Pless / U.

Petrausch Eud What’s the Role for Immunotherapy With and Without Chemotherapy in Oncogene Mutated NSCLC? Corey J. Langer 19min https://meetinglibrary.asco.org/record/167455/videoChair: N. Pless / U.

Petrausch Edu The Next Frontier: Understanding and Overcoming Resistance to Targeted Therapy and Immunotherapy Pradnya Dinkar Patil16min https://meetinglibrary.asco.org/record/167441/video

15:00-15:30 Coffee Break

15:30-17:30

Chairmen

VM Session II - 2h

Abstract #

Chair: U. Gueller / D.

HelblingEdu Systemic Therapy for Anal Squamous Cell Carcinoma Cathy Eng 11min https://meetinglibrary.asco.org/record/167357/video

Chair: U. Gueller / D.

HelblingEdu Cancer Prevention Through Human Papillomavirus Vaccination Joes Paflesky 15min https://meetinglibrary.asco.org/record/167366/videoChair: T. Ruhstaller / P.

Weder Debate Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant Systemic Therapy Neumann 15min https://meetinglibrary.asco.org/record/168039/videoChair: T. Ruhstaller / P.

Weder Debate

Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant

Systemic Therapy Bedrosian 7min https://meetinglibrary.asco.org/record/167342/videoChair: T. Ruhstaller / P.

Weder Debate

Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant

Systemic Therapy Mamounas 7min https://meetinglibrary.asco.org/record/167417/video

Chair: S. Hofer Suggestions Sarcoma Efficacy of low dose pazopanib in advanced soft tissue sarcoma (STS)Abstr e22555 Silvia Hofer 10min ppt presentation by Slivia Hofer

17:30 End of Scientific Program

19:00 Dinner Buffet

Monday / June 3, 2019 Abstract Title Presenter Duration Link VM Start VM at Link Abstract Comments

8:30-8:35

Practice Changing Highlights day 1 &

Outlook

8:35-10:00

Chairmen

VM Session III - 1h25

Abstract #

Ulrich Güller/Daniel Helbling 3501Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-

based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).Timothy Iveson 12 min https://meetinglibrary.asco.org/record/171153/video

Ulrich Güller/Daniel Helbling Short Educational IDEA 3 vs 6 m of chemo Ulrich Güller 10 min

Ulrich Güller/Daniel Helbling 3504FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant

chemotherapy (NAC) for colon cancer.Matthew T. Seymour 12 min https://meetinglibrary.asco.org/record/171160/video

Ulrich Güller/Daniel Helbling 3508Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line

treatment of unresectable mCRC.Chiara Cremolini 12 min https://meetinglibrary.asco.org/record/171184/video

Ulrich Güller/Daniel Helbling LBA 4Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients

(pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.Hedy L. Kindler 13 min https://meetinglibrary.asco.org/record/174488/video

10:00-10:30 Coffee Break

10:30-12:00

Chairmen

VM Session IV - 1h30

Abstract #

Ulrich Güller/Daniel Helbling 4000APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus

gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.Margaret A Tempero 10 min https://meetinglibrary.asco.org/record/173181/video

Ulrich Güller/Daniel Helbling 4003

ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or

ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced /

metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem)

chemotherapy.

Angela Lamarca 12 min https://meetinglibrary.asco.org/record/173183/video

Ulrich Güller/Daniel Helbling 4004Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for

second line therapy in advanced hepatocellular carcinoma (HCC).Richard S Finn https://meetinglibrary.asco.org/record/173190/video

Ulrich Güller/Daniel Helbling LBA4007Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or

gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.Joseph Tabernero 13 min https://meetinglibrary.asco.org/record/173187/video

Ulrich Güller/Daniel Helbling 4006Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer

(aGOAC): The GO2 phase III trial. Peter S HallPeter S Hall 12 min https://meetinglibrary.asco.org/record/173850/video

Ulrich Güller/Daniel Helbling 4002A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation

for small hepatocellular carcinoma (SURF trial).Namiki Izumi 12 min https://meetinglibrary.asco.org/record/174776/video

12:00-13:15 Lunch

13:15-14:00

Chairmen

VM Session V - 45'

Abstract #

Christoph Driessen Educational Octagenarians with Multiple Myeloma Sonja Zweegman 15 min https://meetinglibrary.asco.org/record/167897/video

Christoph Driessen 8003Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs

VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.Philippe Moreau 12 min https://meetinglibrary.asco.org/record/172374/video

Christoph Driessen 8005Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC)

versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory

multiple myeloma (RRMM): COLUMBA.

Maria-Victoria Mateos 12 min https://meetinglibrary.asco.org/record/174838/video

14:00-15:00 Live Session

Moderation:

Daniel Helbling Dr. med. Stefan Zimmermann Neoadjuvant Therapy: Should Medical Oncologists Go First? Jordan D. Berlin, MD, FASCO / Vanderbilt University

Daniel Helbling Dr. med. Stefan Zimmermann

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line

treatment of unresectable mCRC Chiara Cremolini, MD / Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana

Ulrich Güller Dr. med. Stefan Zimmermann

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus

gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma Margaret A. Tempero, M.D. / Director, UCSF Pancreas Center

15:00-15:30 Coffee Break15:30-17:30

Chairmen

VM Session VI - 2h

Abstract #

Silvia Hofer LBA3ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox)

+ olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).William D. Tap 15 min https://meetinglibrary.asco.org/record/174690/video

Silvia Hofer Poster Discussion Building the Evidence for Immunotherapy in Sarcoma Thierry Alcindor 5 min https://meetinglibrary.asco.org/record/175573/video

Jörg Beyer Plenary sessionOverall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without

enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an

ANZUP-led international cooperative group tria

Christopher Sweeney 20 min https://meetinglibrary.asco.org/record/174531/video

Jörg Beyer Plenary session Discussion ENZAMET Tanya B. Dorff 15 min https://meetinglibrary.asco.org/record/178202/video

Thomas Ruhstaller DebateComplete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant

Systemic Therapy Heather B. Neuman 15 min https://meetinglibrary.asco.org/record/168039/video

Thomas Ruhstaller DebateComplete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant

Systemic Therapy Isabelle Bedrosian 7 min https://meetinglibrary.asco.org/record/167342/video

Thomas Ruhstaller DebateComplete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant

Systemic Therapy Eleftherios P. Mamounas 7 min https://meetinglibrary.asco.org/record/167417/video

Ulf Petrausch Case Case 3: Managing Immunotherapy in Patients with Renal Insufficiency (PD-L1 Low) Melissa Lynne Johnson 60 min https://meetinglibrary.asco.org/record/167469/video

17:30 End

19:30 Apéro & Dinner Buffet

Tuesday / June 4, 2019 Abstract Title Presenter Duration Link VM

8:30-8:35 Practice Changing Highlights day 2 & Outlook

8:35-10:00Chairmen VM Session VII - 1h25Abstract #

Ulf Petrausch 6000Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab

(pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell

carcinoma (R/M HNSCC).

Danny Rischin 12 min https://meetinglibrary.asco.org/record/171051/video

Ulf Petrausch Wolfram: Erklärung Immumo-Scores für Onkologen 10 min

Ulf Petrausch 9001Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin

chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer

(gef vs gef+C).

Vanita Noronha 13 min https://meetinglibrary.asco.org/record/173366/video

Ulf Petrausch Chemotherapy and Antiangiogenic Therapy in 2019: Who Needs It? 8 min https://meetinglibrary.asco.org/record/174735/video

Ulf Petrausch 9004Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC):

Efficacy data from the phase II GEOMETRY mono-1 study.Juergen Wolf 13 min https://meetinglibrary.asco.org/record/173357/video

Ulf Petrausch New Drugs and Resistance: Have We MET Expectations? 6 min https://meetinglibrary.asco.org/record/174909/video

Ulf Petrausch 9007 Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Pasi A. Janne 13 min https://meetinglibrary.asco.org/record/174631/video

10:00-10:30 Coffee Break

10:30-12:00Chairmen VM Session VIII - 1h30Abstract #

Thomas Ruhstaller 500

Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab

emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive

breast cancer (BC): Final outcome results from the phase III KRISTINE study. Hurvitz https://meetinglibrary.asco.org/record/172055/video

Thomas Ruhstaller 501

Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant

treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial

identifying a new potential de-escalation standard? Jonas Bergh https://meetinglibrary.asco.org/record/172373/video

Thomas Ruhstaller 502

HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab:

Results from a prospective clinical trial Otto Metzger Filho https://meetinglibrary.asco.org/record/174997/video

Thomas Ruhstaller Disc Anti-HER2 Therapy at the Forefront: Stepping Closer to De-escalation Pelgram https://meetinglibrary.asco.org/record/177343/video

Jörg Beyer 4500Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for

metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC

intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Brian I. Rini 12 min https://meetinglibrary.asco.org/record/171839/video

Jörg Beyer Discussant Evolving Front-Line Therapy in Metastatic Renal Cell Carcinoma Rana McKay 12 min https://meetinglibrary.asco.org/record/175123/video

12:00-13:15 Lunch

13:15-14:00Chairmen VM Session IX - 45'Abstract #

Jörg Beyer 4502Randomized, double-blind phase III study of pazopanib versus placebo in patients with

metastatic renal cell carcinoma who have no evidence of disease following

metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

Leonard Joseph Appleman 12 min https://meetinglibrary.asco.org/record/171840/video

Jörg Beyer 4503CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial

comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with

metastatic urothelial carcinoma.

Jonathan E. Rosenberg 12 min https://meetinglibrary.asco.org/record/171835/video

Silvia Hofer 2000Second interim and first molecular analysis of the EORTC randomized phase III intergroup

CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without

1p/19q codeletion�

Martin J. Van Den Bent

14:00-15:00 Live Session

Moderation:

Ulf Petrausch Dr. med. Stefan Zimmermann

What Do I Do: Immune Toxicity? Overview of Immunotherapy Toxicity? Oncologist

Overview Mario Sznol, MD / Yale School of Medicine and Smilow Cancer Center, Yale New Haven Hospital

J. Beyer Dr. med. Stefan Zimmermann

“Treatment choices in first-line metastatic renal cancer and perioperative/metastatic

bladder cancer”? PD Dr. med. Aurelius Omlin / KSSG

cancelled in last minute:

Ulrich Güller Dr. med. Stefan Zimmermann POSTER DISCUSSION SESSION: Gastrointestinal (Colorectal) Cancer Fotios Loupakis, MD, PhD / Istituto Toscano Tumori

15:00-15:30 Coffee Break

15:30-17:30Chairmen VM Session X - 2hAbstract #

Patrik Weder 5500

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus

ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent

carcinosarcoma of the uterus or ovary: An NRG oncology trial.

Matthew A. Powell 12 min https://meetinglibrary.asco.org/record/173464/video

Patrik Weder 5502Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable

(MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated

recurrent/persistent endometrial cancer (EC).

Panagiotis A. Konstantinopoulos 12 min https://meetinglibrary.asco.org/record/173434/video

Patrik Weder 5503Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation

for stage Ib2-IIb cervical cancer, EORTC 55994.Gemma Kenter 12 min https://meetinglibrary.asco.org/record/173453/video

Patrik Weder 5506Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm)

platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.Richard T. Penson 12 min https://meetinglibrary.asco.org/record/173435/video

Patrik Weder 5505Combination of niraparib and bevacizumab versus niraparib alone as treatment of

recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free

study—NSGO-AVANOVA2/ENGOT-OV24.

Mansoor Raza Mirza 12 min https://meetinglibrary.asco.org/record/173447/video

Brigitta Baumert 11001STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus

surgery versus surgery alone for patients with retroperitoneal sarcoma.Sylvie Bonvalot 12 min https://meetinglibrary.asco.org/record/174255/video

17:30 End

19:00 Dinner Buffet Terrace

Wednesday / June 5, 2019 Abstract Title Presenter Duration Link VM

8:30-8:35 Practice Changing Highlights day 2 & Outlook

8:35-10:00Chairmen VM Session XI - 1h25Abstract #

Weder Patrik 1002

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer

previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA

trial.

Cristina Saura 12 min https://meetinglibrary.asco.org/record/170932/video

Weder Patrik 1003

IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III

study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-

negative breast cancer (mTNBC).

Peter Schmid 12 min https://meetinglibrary.asco.org/record/170934/video

Ruhstaller Thomas 1005

Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an

aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-

controlled, phase II trial.

Robert Hugh Jones 12 min https://meetinglibrary.asco.org/record/170933/video

Ruhstaller thomas 1007

A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in

premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10,

NCT02592746).

Yeon Hee Park 12 min https://meetinglibrary.asco.org/record/174497/video

Ruhstaller Thomas 1008Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated

with endocrine therapy ± ribociclib: Overall survival (OS) results.Sara A. Hurvitz 12 min https://meetinglibrary.asco.org/record/174827/video

10:00-10:30 Coffee Break

10:30-11:45Chairmen VM Session XII - 1h30Abstract #

Ulrich Güller / Daniel Helbling 4004Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line

therapy in advanced hepatocellular carcinoma (HCC).Richard S Finn 12 min https://meetinglibrary.asco.org/record/173190/video

Ulrich Güller / Daniel Helbling Short Presentation HCC and IDEA Güller PPT, 3 min

Ulrich Güller / Daniel Helbling 4006Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The

GO2 phase III trial. Peter S HallPeter S Hall 12 min https://meetinglibrary.asco.org/record/173850/video

Ulrich Güller / Daniel Helbling 4002A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small

hepatocellular carcinoma (SURF trial).Namiki Izumi 12 min https://meetinglibrary.asco.org/record/174776/video

11:45

Wrap Up (Practice Changing Highlights) & Good

Bye

12:00-13:15 Lunch